Cancer Research · 2008 · 85 citations · 34 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryMolecular PharmacologyTargeted Drug DeliveryCancer Drug DeliveryLiposomal FormulationsLiposome-based DeliveryNanocarriers For TherapeuticsRna InterferenceSmall Interfering Rna DeliveryCationic LiposomesLipid-based Drug CarriersLiposomesMrna DeliveryPegylated LiposomesPhase Transition TemperatureReduced Drug UptakeTherapeutic Small Interfering Rna
The pharmacokinetics and antitumor activity of pegylated small interfering RNA (siRNA)/cationic liposome complexes were studied after systemic administration to mice. We designed pegylated-lipid carriers for achieving increased plasma concentrations of RNA and hence improved accumulation of RNA in tumors by the enhanced permeability and retention effect. We compared the pharmacokinetics of siRNA complexed with liposomes incorporating pegylated lipids with longer (C-17 or C-18), shorter (C-12 to C-16), or unsaturated (C-18:1) acyl chains. When longer acyl chains were used, the plasma concentrations of siRNA obtained were dramatically higher than when shorter or unsaturated chains were used. This may be explained by the higher gel-to-liquid-crystalline phase-transition temperature (Tc) of lipids with longer acyl chains, which may form more rigid liposomes with reduced uptake by the liver. We tested a siRNA that is sequence specific for the antiapoptotic bcl-2 mRNA complexed with a pegylated liposome incorporating a C-18 lipid (PEG-LIC) by i.v. administration in a mouse model of human prostate cancer. Three-fold higher accumulation of RNA in the tumors was achieved when PEG-LIC rather than nonpegylated liposomes was used, and sequence-specific antitumor activity was observed. Our siRNA/PEG-LIC complex showed no side effects on repeated administration and the strength of its antitumor activity may be attributed to its high uptake by the tumors. Pegylation of liposomes improved the plasma retention, uptake by s.c. tumors, and antitumor activity of the encapsulated siRNA. PEG-LIC is a promising candidate for siRNA cancer therapy.
34
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Andrew Fire, Siqun Xu, Mary K. Montgomery et al. · Nature · 1998 · 15.3K citations · Full text
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
Theresa M. Allen, Cecilie Cetti Hansen, Francisco J. Plaza Martín et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1991 · 1.4K citations